Vetoquinol SA

V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
  • TickerVETO
  • ISINFR0004186856
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 03/22/2019

...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 22/03/2019

...

Christophe-Raphaël Ganet

Vetoquinol : Feedback from analysts’ meeting: a solid trajectory but less upside in the short term

>2019: a year at cruising speed? - From the meeting, we retain the following points:1- Sales guidance: no official guidance but we understand that 2019 sales up +3/5% on an organic basis would be a legitimate target given growth in the animal health market (around +4% with significantly diverging trends by region as Europe, which accounts for almost 50% of Vétoquinol’s sales, is forecast up 1.5%-2%e due to measures targeting the limiting of antibiotic use,  unli...

Christophe-Raphaël Ganet

Vetoquinol : Feedback réunion d’analystes : trajectoire solide mais moins d’upside CT

>2019 : une année régime de croisière ? - Au sortir de la réunion, nous retenons :1- Guidances de CA : pas de guidance officielle mais nous comprenons qu'un CA 2019 à +3/5% organique serait un objectif légitime compte tenu de la croissance du marché de la santé animale (autour de +4% avec pas mal de contraste par zone puisque l'Europe, proche de 50% du CA de Vétoquinol, ne progresse que de 1,5%/2%e en raison des mesures visant à limiter l'usage des antibiotiques,...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Jeremy Garnier
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Nicolas David
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/21/2019

...

Christophe-Raphaël Ganet

Vetoquinol : Feedback from analysts’ meeting: a solid trajectory but less upside in the short term

>2019: a year at cruising speed? - From the meeting, we retain the following points:1- Sales guidance: no official guidance but we understand that 2019 sales up +3/5% on an organic basis would be a legitimate target given growth in the animal health market (around +4% with significantly diverging trends by region as Europe, which accounts for almost 50% of Vétoquinol’s sales, is forecast up 1.5%-2%e due to measures targeting the limiting of antibiotic use,  unli...

Christophe-Raphaël Ganet

Vetoquinol : Feedback réunion d’analystes : trajectoire solide mais moins d’upside CT

>2019 : une année régime de croisière ? - Au sortir de la réunion, nous retenons :1- Guidances de CA : pas de guidance officielle mais nous comprenons qu'un CA 2019 à +3/5% organique serait un objectif légitime compte tenu de la croissance du marché de la santé animale (autour de +4% avec pas mal de contraste par zone puisque l'Europe, proche de 50% du CA de Vétoquinol, ne progresse que de 1,5%/2%e en raison des mesures visant à limiter l'usage des antibiotiques,...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Jeremy Garnier
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Nicolas David
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/21/2019

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Jeremy Garnier
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Nicolas David
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 21/03/2019

...

Christophe-Raphaël Ganet

Vetoquinol : 2018 results in line – less upside except perhaps from M&A – downgrade to Neutral (vs Buy) – forecasts and target price adjusted (€ 60 vs € 57)

>Underlying operating profit in line (€ 48m) thanks to mix effects - EBITDA came in at € 60.4m, i.e. 16.4% of sales. Vetoquinol's 2018 underlying operating profit rose by 5.3% to € 48.4m. Net profit came in at € 36.3m (+4%) with a higher tax rate than in 2017 which had benefited from the gain from a disputed claim, the lower tax rate in the US, underlying negative forex and the earnings mix between subsidiaries: 25.1% vs 19.3% at end-December 2017. The cash posit...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 03/22/2019

...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 22/03/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/08/2019 Date Performance since listing Date Performance since listing

Sixt Leasing, an independent player in the German vehicle leasing and fleet management market, stands out for its strong momentum in the online retail and fleet management segments and its capacity to handle the diesel risk effectively. These strengths should pave the way for buoyant growth over the coming years (2018-2021e CAGR of +8% for revenue and 15% for pre-tax profit) and a rerating of the stock (target price € 18.1, i.e. 34% upside). We are initiating coverage of the stock wit...

Alfred Glaser ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Geoffroy Michalet
  • Jean Sassus
  • Jerôme Bodin
  • Manuel Martin
  • Michael Foundoukidis
  • Steven Gould
  • Sven Edelfelt
  • Sylvain Goyon
  • Thomas Effler
  • Valentin Pernet
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/08/2019

An objective examination of the growth drivers of indices (macroeconomic growth expectations, EPS momentum, monetary conditions and the cost of capital) leads us to believe that the momentum observed since the start of the year cannot be maintained in the short term. In short, the market (Stoxx 600) is ahead of its transition times and should enter a fluctuation band that we estimate at between 355 and 384 points. Consequently, the most rational attitude consists in a total or partial...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 08/03/2019

Sixt Leasing, acteur indépendant du marché allemand du leasing de véhicules et de gestion de flottes, se distingue par sa forte dynamique sur les segments Online Retail et Fleet Management, ainsi que par sa capacité à gérer efficacement le risque diesel. Ces atouts se traduiront par une croissance soutenue sur les prochaines années (TMVA18-21e CA : +8% ; RCAI : 15%) et par une revalorisation du titre (OC 18.1 €, soit un potentiel de 34%). Nous initions la couverture avec une opinion A...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Dechra Pharmaceuticals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Dechra Pharmaceuticals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Dechra Pharmaceuticals PLC since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

MarketLine Department

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Onxeo SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This ...

Jehanne Leroy

Proxy Report - 29/05/2018

Proxinvest attire l'attention des actionnaires sur les points suivants : Tout d'abord, notons que le Conseil d'administration de la société est largement dominé par la famille Frechin, actionnaire de contrôle, qui est représentée par 5 sièges sur 9 (55,6%). Par ailleurs, Proxinvest regrette que la société maintienne la possibilité de l'usage de ses délégations financières en période d'offre publique, ce qui n'est pas favorable aux intérêts des actionnaires puisque cela peut être considéré comme la mise en place d'un arsenal anti-OPA. Enfin, la communication de la société concernant les rémun...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch